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Pathology, RWTH University of Aachen, Aachen, GermanyBackground & Aims: Epiplakin is a member of the plakin protein
family and exclusively expressed in epithelial tissues where it
binds to keratins. Epiplakin-deﬁcient (Eppk1/) mice displayed
no obvious spontaneous phenotype, but their keratinocytes
showed a faster keratin network breakdown in response to stress.
The role of epiplakin in the stressed liver remained to be
elucidated.
Methods:Wild-type (WT) and Eppk1/ mice were subjected to
common bile duct ligation (CBDL) or fed with a 3,5-diethoxycar-
bonyl-1,4-dihydrocollidine (DDC)-containing diet. The impor-
tance of epiplakin during keratin reorganization was assessed
in primary hepatocytes.
Results: Our experiments revealed that epiplakin is expressed in
hepatocytes and cholangiocytes, and binds to keratin 8 (K8) and
K18 via multiple domains. In several liver stress models epiplakin
and K8 genes displayed identical expression patterns and trans-
genic K8 overexpression resulted in elevated hepatic epiplakin
levels. After CBDL and DDC treatment, Eppk1/ mice developed
a more pronounced liver injury and their livers contained larger
amounts of hepatocellular keratin granules, indicating impaired
disease-induced keratin network reorganization. In line with
these ﬁndings, primary Eppk1/ hepatocytes showed increased
formation of keratin aggregates after treatment with the phos-
phatase inhibitor okadaic acid, a phenotype which was rescuedJournal of Hepatology 20
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Finally, transfection experiments revealed that Eppk1/ primary
hepatocytes were less able to tolerate forced K8 overexpression
and that TMAO treatment rescued this phenotype.
Conclusion: Our data indicate that epiplakin plays a protective
role during experimental liver injuries by chaperoning disease-
induced keratin reorganization.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY license.Introduction
Epiplakin is a large protein (>700 kDa) that was originally identi-
ﬁed as an autoantigen in the serum of a patient suffering from a
subepidermal blistering disease [1]. Encoded by a single exon,
epiplakin consists entirely of 13 consecutive plakin repeat
domains (PRDs) in humans and 16 repeats in mice [2,3]. PRDs
are a hallmark of proteins belonging to the plakin family which
organize the cytoskeleton by binding and interlinking cytoskele-
tal ﬁlaments (for review see [4]). The absence of any other pro-
tein domains usually found in plakins makes epiplakin a unique
and enigmatic protein.
Expression of epiplakin is restricted to epithelial tissues
including simple epithelia of the digestive system [2,3].
Additional studies revealed that epiplakin binds to intermediate
ﬁlaments, especially keratins, of simple as well as of stratiﬁed
epithelia [5,6]. Surprisingly and in contrast to other plakins, tar-
geted inactivation of epiplakin in mice revealed no obvious
in vivo phenotype [7], apart from accelerated keratinocyte migra-
tion during wound healing [8]. Subsequent ex vivo analyses sug-
gested functions for epiplakin in stress response, as epiplakin-
deﬁcient (Eppk1/) keratinocytes displayed aggravated keratin
disruption upon treatment with phosphatase inhibitors [6]. In
addition, Eppk1/ corneal epithelium exhibited increased fragi-
lity upon mechanical intervention [9]. Recently, we showed that
epiplakin deﬁciency aggravated experimentally induced pancre-
atitis [10] indicating a protective role in simple epithelia.
The major binding partners of epiplakin identiﬁed so far are
keratins including keratin 8 and 18 (K8 and K18), the most15 vol. 62 j 1357–1366
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frequent keratin heteropolymer expressed in simple epithelia. K8
and K18 play a substantial role in health and disease of simple
epithelia, as most comprehensively studied in liver (for review
see [11]). During various stress conditions keratin expression is
upregulated in liver, which might promote important cytoprotec-
tive functions [12]. In adult mice, the only keratins expressed in
hepatocytes are K8 and K18, whereas cholangiocytes additionally
express K7 and K19 [13].
In the liver of mice, keratin deﬁciencies such as total lack of K8
or K18 and certain mutations in their genes lead to hepatic phe-
notypes (for review see [11]). Several human K8 and K18 muta-
tions have been described that predispose transgenic mice to
both mechanically- and non-mechanically-induced liver injuries
(for review see [11]). K8 and K18 variants identiﬁed in human
patients predispose to the development and adverse outcome
of various liver disorders such as chronic hepatitis C, primary bil-
iary cirrhosis or acute liver failure [11,14,15].
Given that epiplakin has not only been shown to be expressed
in liver [3,16] but also to interact with K8/K18 [5] and to be of
importance during stress response [6], we aimed to investigate
epiplakin’s function in liver under various stress conditions.
For this purpose, we studied the expression of epiplakin upon
stress induction and its importance in two liver injury mouse
models, i.e. common bile duct ligation (CBDL) and 3,5-diethoxy-
carbonyl-1,4-dihydrocollidine (DDC) treatment. Additionally,
two different ex vivo approaches were used to analyze epiplakin’s
function during keratin reorganization in primary hepatocytes.B
C
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Fig. 1. Epiplakin is expressed in hepatocytes and cholangiocytes, and colo-
calizes with hepatic K8 and K19. (A and B) IFM depicting the localization of
epiplakin and keratins in murine liver. Immunolabeling of epiplakin (A and B) and
K8 (A) or K19 (B) on parafﬁn sections of livers from WT and Eppk1/ mice. Scale
bars: 20 lm. (C) Immunoﬂuorescent labeling of epiplakin demonstrated diffuse
protein localization in livers of Krt8/ mice, as opposed to the ﬁlamentous
epiplakin pattern colocalizing with the keratin network in WT organs (A and B).
Scale bars: 20 lm.Materials and methods
Animal experiments
All animal experiments were in accordance with Austrian Federal Government
laws and regulations or approved by the State of Baden-Wurttemberg
(Germany) and the University of Ulm (Germany) Animal Care Committee [experi-
mental protocol for carbon tetrachloride (CCl4)-induced liver ﬁbrosis develop-
ment]. The previously described Eppk1/ mice [7] were backcrossed into the
C57BL/6J background (N10) and all experiments were performed using age-
and sex-matched littermate mice. Additionally, K8-deﬁcient (Krt8/) mice [17]
and mice overexpressing human K8 [18] were included in this study. Mice were
either subjected to CBDL, a diet supplemented with 0.1% DDC, or CCl4-treatment.
Details for all mouse injury models are provided in Supplementary methods.
Cell culture
Primary hepatocytes from wild-type (WT) and Eppk1/ mice were isolated by a
two-step collagenase perfusion, enriched by differential centrifugation using a
Percoll gradient (Sigma, St Louis, MO) and seeded on collagen-coated dishes.
For detailed information on treatment of cells with okadaic acid (OA), transfection
experiments and treatment with trimethylamine N-oxide (TMAO), see
Supplementary methods.
Biostatistical analyses
Values of two groups were compared using unpaired two-tailed Student’s t test or
Mann-Whitney rank sum test. Statistical analyses were performed using
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA). p values <0.05 were con-
sidered statistically signiﬁcant. Data are expressed as mean ± standard error of
the mean (SEM).
Supplementary methods
Histological, immunohistochemical and immunoﬂuorescence analyses as well as
quantitative real-time polymerase chain reaction (qRT-PCR) are described in
detail in Supplementary methods. Additionally, comprehensive descriptions of1358 Journal of Hepatology 2015biochemical analyses including preparation of tissue lysates, immunoblotting,
blot overlay and pull-down assays along with a detailed list of the antibodies used
are provided.Results
Epiplakin is expressed in hepatocytes and cholangiocytes
In the past, expression of epiplakin in liver was shown to be
either conﬁned to hepatocytes [3] or to cholangiocytes with only
barely detectable epiplakin levels in hepatocytes [16]. Hence, in
order to characterize the localization of epiplakin in liver in more
detail, double-immuno-ﬂuorescence stainings for epiplakin andvol. 62 j 1357–1366
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Fig. 2. Parallel upregulation of K8 and epiplakin in livers of mice subjected to
various forms of stress and of mice overexpressing human K8. (A) qRT-PCR
analysis demonstrating that upon CBDL and DDC feeding, both K8 (Krt8) and
epiplakin (Eppk1) mRNA levels are increased signiﬁcantly, whereas CCl4 treatment
does neither induce upregulation of K8 nor epiplakin mRNA levels. Data are
expressed as mean ± SEM; n P4; ⁄⁄⁄p <0.0005; n.s., not signiﬁcant. (B) IHC for
epiplakin and K8 in healthy, CBDL-, DDC- and CCl4-treated livers of WT mice.
Scale bars: 100 lm. (C) qRT-PCR analysis demonstrating epiplakin mRNA upreg-
ulation in liver of mice overexpressing human K8. Data are expressed as
mean ± SEM; n P5; ⁄⁄p <0.005.
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either K8 or K19, the latter representing a speciﬁc marker of
cholangiocytes, were performed. In livers of WT mice epiplakin
was expressed in hepatocytes, whereby its staining pattern clo-
sely resembled that of keratin ﬁlaments (Fig. 1A). Furthermore,
much stronger epiplakin signals than in hepatocytes were
detected in cholangiocytes, where the protein colocalized with
K19 (Fig. 1B). Accordingly, qRT-PCR analysis revealed that epi-
plakin mRNA levels were signiﬁcantly higher in common bile
duct and gall bladder than in liver (Supplementary Fig. 1).
Epiplakin binds to K8 and K18 via multiple domains
Previous studies have demonstrated that nearly all PRDs of epi-
plakin bind to epidermal keratins [6,19] whereas up until now
only themost C-terminal PRD of human epiplakin has been shown
to bind to K8/K18 [5]. Using individual PRDs of mouse epiplakin
(Supplementary Fig. 2A), we showed that epiplakin directly binds
to K8 and K18 via multiple domains in a blot overlay assay
(Supplementary Fig. 2B). These ﬁndings were supported by an
additional approach by transfecting primary hepatocytes with
plasmids coding for individual epiplakin PRD-EGFP-fusion pro-
teins, most of which colocalized with keratins (Supplementary
Fig. 2C). The data obtained from blot overlay assays and transfec-
tion experiments are summarized in Supplementary material,
Supplementary Table 1 and Supplementary Fig. 2D. Additionally,
a pull-down assay revealed that soluble K8 co-sedimented with
two recombinant PRDs, indicating interaction between soluble
keratin subunits and epiplakin (Supplementary Fig. 2E).
To address the importance of keratins for epiplakin
distribution, we analyzed the livers of Krt8/ mice for their
epiplakin staining pattern. In the absence of keratin ﬁlaments, a
diffuse cytoplasmic localization of epiplakin was observed in
hepatocytes (Fig. 1C), indicating that epiplakin does not bind to
cytoskeletal ﬁlaments other than keratins. Moreover, this experi-
ment demonstrated that in hepatocytes the presence of keratin
ﬁlaments is a prerequisite for the ﬁlamentous epiplakin localiza-
tion normally found in WT cells.
Eppk1/ mice display no obvious liver phenotype under physiological
conditions
Conﬁrming earlier ﬁndings [7], in untreated livers of
Eppk1/ mice, no obvious differences in keratin ﬁlament
organization were detected (Fig. 1A and B). Furthermore, when
examining the livers of Eppk1/ mice under physiological condi-
tions, no obvious abnormalities in liver morphology were noted
and normal liver enzyme levels were measured in serum of
Eppk1/mice (Table 1). As epiplakin deﬁciency has been reportedTable 1. Serum liver enzyme levels in WT and Eppk1/ mice under various experimental conditions.
Untreated CBDL DDC
WT (n = 5) Eppk1–/– (n = 5) WT (n = 9) Eppk1–/– (n = 7) WT (n = 6) Eppk1–/– (n = 7)
ALT (U/L) 32.3 ± 6.0 27.8 ± 14.0 444 ± 81 1104 ± 131† 1032 ± 125 1671 ± 255*
Bilirubin (mg/dl) b.d.l. b.d.l. 7.6 ± 1.0 12.7 ± 3.1 13.9 ± 1.2 12.9 ± 1.4
ALP (U/L) 86 ± 12 83 ± 10 509 ± 58 809 ± 187 1352 ± 165 1348 ± 177
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; b.d.l., below detection limit. Data are expressed as mean ± SEM. ⁄p <0.05; p <0.005; WT vs.
Eppk1/ using unpaired Student’s t test or Mann-Whitney rank sum test.
Journal of Hepatology 2015 vol. 62 j 1357–1366 1359
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to be responsible for reduced expression of the tight junction pro-
tein E-cadherin in corneal epithelium [9], we investigatedwhether
cellular junctions were affected in the livers of Eppk1/
mice. However, when analyzing the morphology of desmosomes,
adherens junctions and tight junctions using antibodies recogniz-
ing the junctional proteins desmoplakin, E-cadherin and occludin,
respectively, no irregularities in their localization or staining
intensity were detected in unstressed livers of Eppk1/ mice
compared to WT livers (Supplementary Fig. 3).
In experimental liver disease models and in K8-overexpressing mice
epiplakin and K8 are upregulated in parallel
Previous studies have suggested a protective function of epi-
plakin during keratin ﬁlament reorganization in response to cel-
lular stress [6]. Hence, we analyzed whether epiplakin
expression in liver is upregulated upon induction of various
forms of stress. We therefore quantiﬁed epiplakin and K8C
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1360 Journal of Hepatology 2015mRNA levels in WT livers subjected to CBDL, DDC feeding or
CCl4-treatment. In line with previous ﬁndings [20,21], K8
expression was markedly upregulated in WT livers upon CBDL
and DDC treatment (Fig. 2A). Strikingly, in both disease models,
K8 upregulation was accompanied by strong epiplakin expres-
sion, whereas in CCl4-treated livers of WT mice neither epiplakin
nor K8 mRNA levels were increased (Fig. 2A). Using immuno-
histochemistry (IHC), we demonstrated that in CBDL- and
DDC- but not in CCl4-treated livers robust epiplakin upreg-
ulation was seen mainly in hepatocytes, closely paralleling the
expression pattern of K8 (Fig. 2B). Interestingly, in mice
overexpressing human K8 [18], epiplakin mRNA levels were also
upregulated (Fig. 2C).
In Eppk1/ mice CBDL results in aggravated liver injury
To test whether the strong upregulation of epiplakin expression
upon CBDL was indicative of a protective function of the protein**
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during obstructive cholestasis, WT and Eppk1/ mice were sub-
jected to CBDL. Five days after surgery, alanine aminotransferase
(ALT) levels were signiﬁcantly increased in serum from
Eppk1/ mice compared to their littermate controls (Table 1).
In addition, Eppk1/ mice showed elevated serum levels of
bilirubin and alkaline phosphatase (ALP), however, no statistical
signiﬁcance was found (Table 1). Moreover, quantitative
histological evaluation of hematoxylin and eosin (H&E)-stained
liver sections revealed signiﬁcantly increased numbers and sizes
of bile infarcts, resulting in considerably larger areas of necrotic
tissue in Eppk1/ livers in comparison to their WT counterparts
(Fig. 3A).
Next, we analyzed the extent of bile duct proliferation, a
regenerative response to liver injury. Ductular reaction was
assessed by histo-pathological evaluation of parafﬁn sections
stained with H&E or immunostained for K19 (Fig. 3B), mor-
phometric analysis of K19-positive areas on liver sections
(Fig. 3C), and immunoblot analysis of K19 levels in total liver pro-
tein lysates fromWT and Eppk1/ mice (Supplementary Fig. 4A).
All experiments demonstrated signiﬁcantly increased numbers
of ductular proliferates as well as higher K19 levels in
Eppk1/ CBDL livers compared to WT controls, indicating aggra-
vated liver injury in Eppk1/ mice.
Eppk1/ livers display impaired keratin reorganization upon CBDL
Mice lacking or overexpressing hepatic keratins are predisposed
to liver disorders development [17,22–24]. Thus, to investigate
a potential impact of epiplakin on keratin expression, we com-
pared total keratin levels in WT and Eppk1/ livers. When total
liver lysates were analyzed by immunoblotting, equal levels of
K8 and K18 were revealed in WT and Eppk1/ livers, in
untreated mice, and in mice subjected to CBDL (Supplementary
Fig. 4B and C). Thus, it was excluded that the aggravated liver
injury observed in Eppk1/ mice was caused by aberrant keratin
expression.
The parallel upregulation of epiplakin and hepatic keratins
upon biliary obstruction suggested a role of epiplakin in the
organization of keratin networks during a stress response.
Therefore, we examined the keratin network in CBDL livers of
WT and Eppk1/ mice. When studying the K8/K18 ﬁlament
organization using immunoﬂuorescence microscopy (IFM), we
observed not only increased density of the keratin network as
described previously for WT mice undergoing CBDL [20], but also
irregular keratin patterns clearly resulting from the formation of
bile infarcts. Additionally, in non-necrotic areas, we noticed
single hepatocytes comprising aggregated keratin structures
(Fig. 3D). While keratin granules were also detectable in WT
hepatocytes, these keratin aggregations were signiﬁcantly more
frequent in Eppk1/ livers (Fig. 3D).
In Eppk1/ mice DDC treatment results in aggravated liver injury
In WT mice subjected to a DDC diet, epiplakin and K8 were both
strongly upregulated (Fig. 2A and B). Hence, in order to analyze
whether lack of epiplakin increases the susceptibility of mice to
DDC-induced liver injury, livers of WT and Eppk1/ mice were
challenged via administration of DDC. After four weeks of DDC
feeding, Eppk1/ mice displayed signiﬁcantly elevated ALT
serum levels compared to WT mice (Table 1), indicating a more
severe course of liver disease. In contrast, bilirubin and ALPJournal of Hepatology 2015serum levels were comparable in sera of WT and Eppk1/ mice
(Table 1), suggesting that epiplakin deﬁciency increased the sus-
ceptibility of hepatocytes to DDC intoxication rather than aggra-
vated cholestatic injury.
In Eppk1/ livers, increased ductular proliferation was noted
during examination of H&E-stained DDC livers (Fig. 4A). Using
morphometric analysis of the bile duct mass (Fig. 4B) as well as
immunoblot analysis of K19 levels in protein lysates
(Supplementary Fig. S5A) of livers from WT and Eppk1/ mice,
signiﬁcantly larger numbers of ductular proliferates or higher
K19 levels, respectively, were detected in Eppk1/ DDC livers
than in WT controls.vol. 62 j 1357–1366 1361
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TMAO. Frequency of the presented staining pattern is indicated below each
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signiﬁcant.
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Eppk1/ livers display impaired keratin reorganization after DDC
treatment
Next, using immunoblot analysis, we investigated whether after
four weeks of DDC administration hepatic keratin expression
was modiﬁed in Eppk1/ livers compared to WT controls. K8
and K18 levels were markedly increased after DDC feeding in liv-
ers from both WT and Eppk1/ mice, but no differences between
both genotypes were observed (Supplementary Fig. 5B and C).
Subsequently, we examined immunoﬂuorescently labeled K8 on
parafﬁn sections obtained from DDC-treated WT and
Eppk1/ livers. Consistent with our observations made during
analysis of CBDL livers, signiﬁcantly more cells comprising ker-
atin granules were detected in DDC-treated Eppk1/ livers than
in their WT counterparts (Fig. 4C).
Aggregates containing K8/K18 are a common pathological fea-
ture of different liver disorders and are most commonly referred
to as Mallory-Denk bodies (MDBs) (for review see [25]). Thus,
using IFM, we analyzed whether the K8 aggregations found in
CBDL- and DDC-treated livers comprised protein markers typical
for MDBs. All keratin aggregates detected in CBDL- and DDC-trea-
ted livers of both genotypes were negative for ubiquitin, p62 and
Hsp70 (Supplementary Fig. 6), and therefore do not correspond to
MDBs.
Hepatocytes comprising keratin aggregates found in CBDL- and
DDC-treated livers are dying
IFM analysis of liver parafﬁn sections derived from WT and
Eppk1/ mice subjected to CBDL or DDC treatment revealed loss
of nuclei in a vast majority of hepatocytes comprising K8 aggre-
gates, indicating that these cells were dying (Supplementary
Fig. 7). As all of these hepatocytes were negative for cleaved cas-
pase-3 (Supplementary Fig. 8), the death of cells comprising
aggregated keratins is likely caused by necrosis rather than by
activation of apoptotic pathways.
WT and Eppk1/ hepatocytes show comparable susceptibility to bile
acid-induced cytotoxicity
To analyze the susceptibility of WT and Eppk1/ hepatocytes to
toxic bile acids as occurring upon local bile leakage into the par-
enchyma, we incubated primary hepatocytes isolated from WT
and Eppk1/ livers with chenodeoxycholic acid (CDCA) or tauro-
cholic acid (TCA). Surprisingly, Eppk1/ hepatocytes were
equally susceptible to bile acid exposure as their WT counter-
parts (Supplementary Fig. 9A). However, in contrast to CBDL-
and DDC-treated livers, no elevation of keratin or epiplakin
expression levels and, consequently, no keratin aggregation was
detected in WT or Eppk1/ hepatocytes upon bile acid exposure
(Supplementary Fig. 9B and C).
Eppk1/ hepatocytes display impaired keratin ﬁlament
reorganization upon OA treatment which can be prevented by the
chemical chaperone TMAO
In order to verify that epiplakin is required during stress-induced
keratin ﬁlament reorganization, primary hepatocytes were trea-
ted with the phosphatase inhibitor OA, which leads to hyper-
phosphorylation of keratins and thereby affects keratin ﬁlament
organization [26,27]. Although total keratin levels are not1362 Journal of Hepatology 2015increased in this stress model, OA treatment strongly elevates
the pool of cytosolic keratins [26,28] associated with the
disassembly of keratin ﬁlaments [26,27].
After exposure of primary hepatocytes to OA, the number of
cells displaying either non-granular or granular keratin network
organization was assessed (Fig. 5A). Eppk1/ hepatocytes were
found signiﬁcantly more often to exhibit granular keratins than
WT cells (Fig. 5A and B). Immunoblot analyses revealed that
the increased keratin network disruption in OA-treated
Eppk1/ hepatocytes was not caused by alterations of the keratin
phosphorylation status (Supplementary Fig. 10).
Interestingly, OA-treated WT and Eppk1/ cells which were
subsequently exposed to bile acids, displayed similar cell death
rates, indicating that increased occurrence of keratin aggregates
does not render hepatocytes more susceptible to bile acid-
induced cytotoxicity (data not shown).
Recently, low molecular weight chemical chaperones have
been shown to protect proteins from aggregating, among them
K5/K14 [29]. Hence, we investigated whether the chaperone
TMAO ameliorates the enhanced OA-induced formation ofvol. 62 j 1357–1366
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keratin aggregates observed in Eppk1/ hepatocytes. For this
purpose, cultivation and OA treatment of hepatocytes were per-
formed in the presence of TMAO. The chaperone was found to sig-
niﬁcantly reduce the number of Eppk1/ hepatocytes comprising
K8 granules by increasing the amount of cells displaying non-
granular keratin (Fig. 5C and D).
Eppk1/ hepatocytes show reduced tolerance for forced K8
overexpression which can be rescued by TMAO
In order to analyze the effect of elevated K8 levels on hepatocytes
as seen during CBDL and DDC treatment, keratin reorganization
in primary hepatocytes was challenged by forced overexpression
of K8. Therefore, WT and Eppk1/ cells were co-cultured and
transfected with a plasmid coding for K8 fused to EYFP or the
empty EYFP vector as a control (Fig. 6A). Remarkably, signiﬁ-
cantly fewer Eppk1/ hepatocytes were found to express
K8-EYFP than their WT counterparts (Fig. 6B), suggesting difﬁcul-
ties of Eppk1/ hepatocytes to cope with high K8 levels.
In transfected hepatocytes, the newly synthesized K8-EYFP
proteins were either integrated in ﬁlaments (non-granular) or
accumulated as keratin granules (Supplementary Fig. 11A). In line
with data from experiments with OA, treatment with TMAO
increased the number of Eppk1/ hepatocytes comprising non-
granular K8-EYFP (Supplementary Fig. 11B and C). Next, we
assessed whether this effect of TMAO was also able to ultimately
rescue the diminished total number of Eppk1/ hepatocytes
tolerating high K8-EYFP levels. Quantiﬁcation of WT andA B
C
Primary hepatocytes 
expressing K8-EYFP 
WT
WT
Fr
eq
ue
nc
y 
of
 K
8-
EY
FP
-
tra
ns
fe
ct
ed
 E
pp
k1
–/
–  c
el
ls
 in
 re
la
tio
n 
to
 W
T 
ce
lls
0.0
0.2
0.4
0.6
0.8
1.0
1.2 n.s. ***
TMAO:
Primary hepatocytes 
expressing K8-EYFP 
0.0
0.2
0.4
0.6
0.8
1.0
1.2 **
Fr
eq
ue
nc
y 
of
 K
8-
EY
FP
-
tra
ns
fe
ct
ed
 c
el
ls
 in
 re
la
tio
n 
to
 u
nt
re
at
ed
 W
T 
ce
lls
WT KO
Transfected with EYFP
WT
KO
WT
KO
K8-EYFP
EYFP
K8-EYFP        Numbers corrected for 
       different transfection rates=
-    + -    +
Eppk1–/–
Eppk1–/–
Fig. 6. Eppk1/ hepatocytes show reduced tolerance for forced K8 expres-
sion, which is rescued by TMAO treatment. (A) Schematic overview showing the
design of primary hepatocytes transfection experiments. WT and Eppk1/
hepatocytes were co-cultivated and transfected with a plasmid encoding K8-EYFP
or EYFP, followed by counting of K8-EYFP- and EYFP-positive cells. To correct for
variations in transfection rate between WT and Eppk1/ hepatocytes in
individual isolations, the number of K8-EYFP-positive cells was divided by the
number of EYFP-positive cells for each single experiment. (B) Signiﬁcantly less
Eppk1/ than WT hepatocytes were found to express EYFP-tagged K8, indicating
difﬁculties of Eppk1/ cells to tolerate high K8 levels. The WT mean was
arbitrarily set to 1. Data are expressed as mean ± SEM; n P140 cells from 6
individual isolations; ⁄⁄p <0.005. (C) Comparison of K8-EYFP-transfected WT and
Eppk1/ hepatocyte numbers cultivated in the absence or presence of TMAO. The
untreated WT mean was arbitrarily set to 1. Data are expressed as mean ± SEM; n
P123 cells from 3 individual isolations; ⁄⁄⁄p <0.0001; n.s., not signiﬁcant.
Journal of Hepatology 2015Eppk1/ cells expressing K8-EYFP demonstrated that signiﬁ-
cantly more K8-EYFP-expressing Eppk1/ cells were found in
the presence of TMAO than in its absence (Fig. 6C).
Taken together, these data showed that TMAO was able to ele-
vate the total number of Eppk1/ hepatocytes expressing K8-
EYFP, which was achieved mainly by increasing the amount of
cells displaying a ﬁlamentous K8-EYFP pattern (summarized in
Supplementary Fig. 11C). These ﬁndings demonstrated that the
aggregation-preventing properties of TMAO rescued the pheno-
type observed in Eppk1/ hepatocytes by enabling them to toler-
ate high keratin levels and, potentially, to avoid cell death
resulting from impaired keratin reorganization.Discussion
Our data show that Eppk1/ mice display no obvious abnormali-
ties in liver, which is in line with previous ﬁndings [7]. Under
physiological conditions, lack of epiplakin does not affect the ker-
atin ﬁlament organization in hepatocytes and the localization of
major cell-cell junction proteins is unaltered. However, after
CBDL and DDC treatment, Eppk1/ mice developed a more pro-
nounced liver injury. Differences in inﬂammatory response are
unlikely to be the primary cause of this phenotype since inﬂam-
matory cells do not express epiplakin and no indications for
enhanced inﬂammatory cell inﬁltration in stressed Eppk1/ liv-
ers were found (data not shown). Furthermore, we currently have
no evidence that increased biliary rupture contributes to the phe-
notypes observed in Eppk1/ mice. Moreover, our data suggest
that Eppk1/ hepatocytes are not more susceptible to cytotoxi-
city conferred by the mere presence of toxic bile acids, but rather
that epiplakin exerts its protective function during stress-in-
duced keratin upregulation and consequent rearrangement of
the keratin network.
Therefore, we propose that during certain stress conditions
epiplakin protects from aggravated liver injury by interacting
with hepatic keratins which are established stress-protective
proteins [12]. This hypothesis is supported by several observa-
tions: i) epiplakin perfectly colocalizes with K8/K18 ﬁlaments
in hepatocytes; ii) most of epiplakin’s 16 PRDs are able to bind
to K8/K18; iii) in several liver stress models, hepatic epiplakin
and K8 are co-regulated on the transcriptional level; iv) the ﬁla-
ment-associated localization of epiplakin in hepatocytes is com-
pletely dependent on K8/K18 as shown in cells devoided of
keratin ﬁlaments; v) upon experimental injury, livers from
Eppk1/ mice contained increased numbers of hepatocytes com-
prising keratin granules.
How does epiplakin’s interaction with keratins protect from
experimental liver disease? In stressed liver, keratin expression
is typically increased up to 3-fold leading to new ﬁlament forma-
tion and strengthening of existing ﬁlaments, which is thought to
promote the important cytoprotective functions provided by K8
and K18 [12]. Keratins represent about 0.3% of total cellular pro-
tein in liver [30]. Given the strong upregulation of keratins during
certain liver disorders, this already high amount is signiﬁcantly
increased within a very short time frame and therefore possibly
challenging the cellular systems ensuring keratin proteostasis.
In this respect, overexpression of several intermediate ﬁlaments
including glial ﬁbrillary acidic protein, peripherin or neuroﬁla-
ments in mice has been shown to be toxic, leading to neurological
disorders affecting the respective organs [31]. In contrast, high
keratin levels in liver per se are generally well tolerated undervol. 62 j 1357–1366 1363
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Fig. 7. Loss of epiplakin impairs stress-induced keratin reorganization
leading to aggravated experimental liver injury. The scheme visualizes a
model of epiplakin’s role during disease-induced or forced keratin upregulation
and consequent ﬁlament reorganization in hepatocytes. In untreated WT cells,
epiplakin (blue) colocalizes with keratin ﬁlaments (brown). Under physiological
conditions (healthy cell), epiplakin deﬁciency does not cause alterations in
keratin network organization. In hepatocytes of both genotypes, keratin network
reorganization is triggered by experimental liver disease-induced keratin upreg-
ulation or by forced keratin expression. Eppk1/ cells suffer from keratin
disorganization which leads to cell death further aggravating liver disease. In
contrast to Eppk1/ hepatocytes, parallel upregulation of epiplakin enables WT
cells to tolerate high keratin protein levels by successfully reorganizing their
keratin ﬁlament networks. N, nucleus.
Research Articlebasal conditions [12]. However, elevated keratin levels are a co-
factor for liver injury as shown by K8 overexpressing mice fed
with a high fat diet, which showed accumulation of K8/K18 and
increased keratin misfolding [24]. This led us to speculate that
disease-induced keratin overexpression without parallel protec-
tive upregulation of epiplakin leads to aggravated liver injury
caused by impaired keratin network reorganization and subse-
quent hepatocellular death. A scheme depicting this model is1364 Journal of Hepatology 2015shown (Fig. 7). This hypothesis is strongly supported by our data
showing that the chemical chaperone TMAO rescues the dimin-
ished number of Eppk1/ hepatocytes artiﬁcially overexpressing
K8. TMAO has been shown to be capable of decreasing the accu-
mulation and aggregation of different proteins [32,33]. In line
with that, TMAO was shown to signiﬁcantly reduce the number
of keratin aggregate-containing keratinocytes derived from
patients suffering from epidermolysis bullosa simplex [29]. The
fact that this chemical chaperone was able to rescue two different
phenotypes observed in primary Eppk1/ hepatocytes strongly
indicates that epiplakin fulﬁlls important keratin chaperone-like
functions in liver.
The importance of proteins chaperoning K8/K18 for cellular
homeostasis was also demonstrated by studies on the co-chaper-
one Mrj (Mammalian relative of DnaJ), showing that its absence
in chorionic trophoblast cells prevents chorioallantoic attach-
ment during placental development [34]. Similar to stressed
Eppk1/ hepatocytes Mrj-deﬁcient chorionic trophoblast cells
displayed keratin aggregates.
Recently, we reported that Eppk1/ mice suffered from
aggravated experimentally-induced pancreatitis, and more of
their acinar cells displayed keratin aggregates [10]. Together with
the new ﬁndings presented in this work these data suggest a gen-
eral function of epiplakin in chaperoning keratins in several
organs comprising of simple epithelia. In contrast, the function
of epiplakin in stratiﬁed epithelia seems to be slightly different,
as indicated by studies showing enhanced migratory potential
of Eppk1/ keratinocytes during wound healing [8] and
increased fragility of corneal epithelium upon mechanical inter-
vention [9]. These ﬁndings are not surprising given that epiplakin
binds to different keratins and that their functions are considered
to be multifactorial and tissue-speciﬁc [11].
The proposed role of epiplakin in chaperoning keratins is
remarkably different from those of most other members of the
plakin protein family. In mice, targeted inactivation of epiplakin
showed no obvious phenotype, whereas mice deﬁcient for other
plakins (e.g. plectin, desmoplakin, bullous pemphigoid antigen
1, and microtubule-actin cross-linking factor 1) revealed severe
phenotypes including early death, skin blistering, and muscle
weakness (for review see [4]). These ﬁndings demonstrate a role
of these plakins in ensuring cellular and tissue integrity upon
mechanical stress. The entirely different function of epiplakin is
possibly based on its exceptional structure comprising solely
PRDs, most of which bind to keratins, whereas many other plakins
interconnect different cytoskeletal ﬁlament systems and cell junc-
tion complexes via speciﬁc binding domains. Thus, epiplakin is an
unusual plakin with regards to both its structure and function.
Further studies are needed to elucidate the precise mecha-
nisms of how epiplakin chaperones the reorganization of keratin
networks and whether these protective functions extend to other
tissues and/or stress situations. In addition, genetic studies could
reveal whether the absence of epiplakin or mutations in its gene
are general risk factors for complications in other pathologies of
the gastrointestinal tract.Financial support
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